Needham analyst Serge Belanger has maintained their bullish stance on BCRX stock, giving a Buy rating on July 24.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Serge Belanger has given his Buy rating due to a combination of factors that highlight BioCryst’s strong performance and future potential. Orladeyo, a key product for the company, has exceeded sales expectations in the second quarter of 2025, showing significant growth both quarter-over-quarter and year-over-year. This impressive performance is attributed to increased prescription rates, improved gross-to-net adjustments, and a notable rise in new patient additions.
Furthermore, despite undergoing leadership changes with a new CEO and CFO, BioCryst is strategically positioning itself as a leader in the rare disease sector through pipeline investments and business development activities. The company’s valuation does not fully reflect Orladeyo’s current sales success and its promising growth trajectory, which supports the Buy rating and a price target of $17.
In another report released on July 24, RBC Capital also reiterated a Buy rating on the stock with a $13.00 price target.